Literature DB >> 26628300

Inflammation and chemerin in colorectal cancer.

Serpil Erdogan1, Fatma Meric Yilmaz2, Ozan Yazici3, Ahmet Yozgat4, Sevilay Sezer5, Nuriye Ozdemir3, Sema Uysal6, Tugrul Purnak7, Mehmet Ali Sendur8, Ersan Ozaslan4.   

Abstract

Chemerin is expressed mainly in the adipose tissue. It is an agonist of chemokine-like receptor-1, which is expressed by the immune system cells. Chemerin stimulates the chemotaxis of the immune system cells, and this indicates the function of chemerin and chemokine-like receptor-1 in the immune response. The tumor microenvironment is very important for determining cancer cell growth and spreading. Therefore, we aimed to investigate the association between colorectal cancer, inflammation, and adipokines including chemerin, adiponectin, and vaspin. The study group consisted of patients with colon cancer, whereas the control subjects consisted of patients with benign conditions, diagnosed with colonoscopy. The two groups were compared in terms of the C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, adiponectin, chemerin, and vaspin. A total of 41 (28 men, 13 women) patients with confirmed colon cancer, and 27 (15 men, 12 women) controls without, confirmed by colonoscopy, were enrolled. The median chemerin levels were found significantly higher in the study group than the controls (390 vs. 340 ng/mL, p = 0.032), whereas the mean vaspin and adiponectin levels were not significantly different. The median values for the CRP, fibrinogen, and ESR were significantly higher in the patients with colon cancer, when compared to the control group (6.08 vs. 1.4 mg/L, p < 0.0001; 408 vs. 359 mg/dL, p = 0.002; and 30 vs. 8 mm/h, p < 0.0001, respectively). Our results show that higher levels of circulating chemerin, CRP, fibrinogen, and ESR are associated with an increased risk of developing colorectal cancer.

Entities:  

Keywords:  C-reactive protein; Chemerin; Colorectal cancer; Erythrocyte sedimentation rate; Fibrinogen; Inflammation

Mesh:

Substances:

Year:  2015        PMID: 26628300     DOI: 10.1007/s13277-015-4483-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  52 in total

1.  Serum adiponectin is not associated with risk of colorectal cancer.

Authors:  Annekatrin Lukanova; Stefan Söderberg; Rudolf Kaaks; Egil Jellum; Pär Stattin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-02       Impact factor: 4.254

2.  Prognostic significance of preoperative fibrinogen in patients with colon cancer.

Authors:  Zhen-Qiang Sun; Xiao-Na Han; Hai-Jiang Wang; Yong Tang; Ze-Liang Zhao; Yan-Li Qu; Rui-Wei Xu; Yan-Yan Liu; Xian-Bo Yu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

Authors:  Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

4.  Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.

Authors:  Lars Møller Pedersen; Tobias Wirenfeldt Klausen; Ulla Høy Davidsen; Hans Erik Johnsen
Journal:  Ann Hematol       Date:  2005-04-15       Impact factor: 3.673

5.  Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity.

Authors:  Valérie Wittamer; Benjamin Bondue; Aude Guillabert; Gilbert Vassart; Marc Parmentier; David Communi
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

6.  Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients.

Authors:  Anna Kumor; Piotr Daniel; Mirosława Pietruczuk; Ewa Małecka-Panas
Journal:  Int J Colorectal Dis       Date:  2008-11-01       Impact factor: 2.571

Review 7.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

Authors:  Mohit Trikha; Robert Corringham; Bernard Klein; Jean-François Rossi
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

8.  Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis.

Authors:  Brian A Zabel; Susumu Nakae; Luis Zúñiga; Ji-Yun Kim; Takao Ohyama; Carsten Alt; Junliang Pan; Hajime Suto; Dulce Soler; Samantha J Allen; Tracy M Handel; Chang Ho Song; Stephen J Galli; Eugene C Butcher
Journal:  J Exp Med       Date:  2008-09-15       Impact factor: 14.307

9.  Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids.

Authors:  Valérie Wittamer; Jean-Denis Franssen; Marisa Vulcano; Jean-François Mirjolet; Emmanuel Le Poul; Isabelle Migeotte; Stéphane Brézillon; Richard Tyldesley; Cédric Blanpain; Michel Detheux; Alberto Mantovani; Silvano Sozzani; Gilbert Vassart; Marc Parmentier; David Communi
Journal:  J Exp Med       Date:  2003-10-06       Impact factor: 14.307

10.  Clinical significance of preoperative inflammatory parameters in gastric cancer patients.

Authors:  Deuk Young Lee; Seong Woo Hong; Yeo Goo Chang; Woo Yong Lee; Byungmo Lee
Journal:  J Gastric Cancer       Date:  2013-06-25       Impact factor: 3.720

View more
  19 in total

1.  Association between systemic inflammation and serum prostate-specific antigen in a healthy Korean population.

Authors:  Jonghyun Yun; Hyunyoung Lee; Wonjae Yang
Journal:  Turk J Urol       Date:  2017-08-01

Review 2.  Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies.

Authors:  Nikolaos Spyrou; Konstantinos I Avgerinos; Christos S Mantzoros; Maria Dalamaga
Journal:  Curr Obes Rep       Date:  2018-12

3.  Immune activity and biodistribution of polypeptide K237 and folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles radiolabeled with 99mTc.

Authors:  Zelai He; Xiangyu Zhang; Jingwen Huang; Yufeng Wu; Xuanzhang Huang; Jie Chen; Junyong Xia; Hao Jiang; Jing Ma; Jian Wu
Journal:  Oncotarget       Date:  2016-11-22

4.  Circulating adipokines are associated with Kawasaki disease.

Authors:  Xin-Yan Zhang; Ting-Ting Yang; Xiu-Fen Hu; Yu Wen; Feng Fang; Hui-Ling Lu
Journal:  Pediatr Rheumatol Online J       Date:  2018-05-08       Impact factor: 3.054

5.  Association of Chemerin Plasma Concentration With Risk of Colorectal Cancer.

Authors:  Fabian Eichelmann; Matthias B Schulze; Clemens Wittenbecher; Juliane Menzel; Cornelia Weikert; Romina di Giuseppe; Ronald Biemann; Berend Isermann; Andreas Fritsche; Heiner Boeing; Krasimira Aleksandrova
Journal:  JAMA Netw Open       Date:  2019-03-01

6.  Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2.

Authors:  J Dinesh Kumar; Iman Aolymat; Laszlo Tiszlavicz; Zita Reisz; Hanan M Garalla; Rob Beynon; Deborah Simpson; Graham J Dockray; Andrea Varro
Journal:  Oncotarget       Date:  2019-01-04

7.  Androgen receptor gene methylation related to colorectal cancer risk.

Authors:  Tingting Xia; Hongru Sun; Hao Huang; Haoran Bi; Rui Pu; Lei Zhang; Yuanyuan Zhang; Ying Liu; Jing Xu; Justina Ucheojor Onwuka; Yupeng Liu; Binbin Cui; Yashuang Zhao
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

Review 8.  More Than an Adipokine: The Complex Roles of Chemerin Signaling in Cancer.

Authors:  Kerry B Goralski; Ashley E Jackson; Brendan T McKeown; Christopher J Sinal
Journal:  Int J Mol Sci       Date:  2019-09-26       Impact factor: 5.923

9.  Assessment of Serum Levels of the Adipocytokine Chemerin in Colorectal Cancer Patients.

Authors:  Manal M Alkady; Phebe L Abdel-Messeih; Neveen M Nosseir
Journal:  J Med Biochem       Date:  2018-07-01       Impact factor: 3.402

Review 10.  Underrated enemy - from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract.

Authors:  Aleksandra Derra; Martyna Bator; Tomasz Menżyk; Michał Kukla
Journal:  Clin Exp Hepatol       Date:  2018-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.